Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | DRD3 | P35462 | 10/20 | 0.54 |
| ▸ | HTR2A | P28223 | 9/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030820 | 1.00 | DRD2 (0.54) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL6819527 | 0.93 | DRD2 (0.51) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL6820522 | 0.93 | DRD2 (0.51) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL6820453 | 0.91 | DRD2 (0.50) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL7024053 | 0.91 | DRD2 (0.50) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL3830330 | 0.91 | DRD2 (0.50) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL7028302 | 0.85 | DRD2 (0.54) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL7029319 | 0.85 | DRD2 (0.54) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL7029323 | 0.85 | DRD2 (0.54) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL6820526 | 0.84 | USP30 (0.49) | DRD2DRD3HTR2AKCNH2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888319-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-6124283-A | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | ASTRA AKTIEBOLAG (SE) | 2000-09-26 | — | — | US | claimed |
| EP-0888319-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034883-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1997-09-25 | — | — | WO | claimed |
| EP-0888319-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-6410530-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-06-25 | — | — | US | disclosed |
| US-6124283-A | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | ASTRA AKTIEBOLAG (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-0888319-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034883-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1997-09-25 | — | — | WO | disclosed |